Search
Mometasone furoate
go.drugbank.com/drugs/DB14512ApprovedInvestigationalVet approvedMometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label][F4292,F4295]. … Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indications[FDA Label][F4292,F4295].
Mixtures: M-FURO FA %0.1 + %2 KREM, 30 G, DERMOTIL-S® UNGUENTOCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersAminoglutethimide
go.drugbank.com/drugs/DB00357ApprovedWithdrawnAminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. … An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2C19 InducersSynonyms: 2-(p-Aminophenyl)-2-ethylglutarimide, 3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidineTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting … TF is a primary initiator of the extrinsic blood coagulation cascade [L38424] and plays a key role in tumor-associated angiogenesis, progression, and metastasis for tumor survival.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAstemizole
go.drugbank.com/drugs/DB00637ApprovedWithdrawnAstemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. … It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Synonyms: 1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole, 1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazoleCategories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexBNT162B2 Omicron (LP.8.1)
go.drugbank.com/drugs/DB23337Approved[L53723] It encodes the spike protein from the Omicron LP.8.1 subvariant of SARS-CoV-2.[L53723] The 2025-2026 formulation of Pfizer-BioNTech's Comirnaty was approved by the US FDA in August 2025. … BNT162B2 Omicron (LP.8.1) is the active ingredient in the 2025-2026 formulation of Pfizer and BioNTech's Comirnaty mRNA vaccine for COVID-19.
Gestrinone
go.drugbank.com/drugs/DB11619ApprovedGestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America. … Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAspartame
go.drugbank.com/drugs/DB00168InvestigationalNutraceuticalFlavoring agent sweeter than sugar, metabolized as phenylalanine and aspartic acid.
Mixtures: HEPASELAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ 500 ML SETLİ ŞİŞE, HEPATAMINE %8 500 ML(SETLI)Categories: Compounds used in a research, industrial, or household settingSevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608] … Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain
Categories: MATE 2-K Inhibitors, MATE 1 InhibitorsAnthrax vaccine
go.drugbank.com/drugs/DB11003ApprovedInvestigational[L47526] It is considered one of the most likely agents to be used in a biological attack. … [L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.
Synonyms: Bacillus anthracis strain V770-NP1-R antigen, Bacillus anthracis strain V770-NP1-R antigensProducts: g/dose (nominal)Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine
go.drugbank.com/drugs/DB16757Approved[L40694] It is composed of VLPs expressing SARS-CoV-2 spike protein trimers (stabilized in a pre-fusion conformation) and is mixed with the AS03 adjuvant system prior to administration. … The Covifenz COVID-19 vaccine (plant-based virus-like particles (VLP), recombinant, adjuvanted) is a plant-based vaccine developed in partnership by Medicago and GlaxoSmithKline which is approved in Canada
Synonyms: Recombinant SARS-CoV-2 spike (S)-protein virus-like particle